Does Anthem Cover Vyvanse? A Complete Insurance Guide

What Is Vyvanse and Why Does Insurance Coverage Matter?

Vyvanse is a prodrug of d-amphetamine approved by the FDA in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [1] Because it remains a brand-name Schedule II controlled substance with limited generic competition, its retail cash price runs approximately $350, $450 per 30-day supply without insurance. [2]

That price gap makes insurance coverage the deciding factor for most patients. Anthem, which operates Blue Cross Blue Shield affiliate plans across 14 states and covers roughly 45 million members, uses a tiered formulary system that directly controls how much you pay at the pharmacy counter. [3]

How Anthem's Tiered Formulary Works

Anthem's formularies typically run four to six tiers. Tier 1 is generic drugs with the lowest copay. Tier 2 covers preferred generics or lower-cost brands. Tier 3 is preferred brand-name drugs. Tier 4 or higher is non-preferred or specialty brands.

Vyvanse almost always lands on Tier 3 or Tier 4 across Anthem commercial plans, depending on the employer group contract and the state. A Tier 3 placement might carry a $60, $90 copay per fill. A Tier 4 placement can push that to $120, $200 or higher before the deductible is met.

Why Prior Authorization Is Typically Required

Prior authorization (PA) is Anthem's process of confirming a drug is medically necessary before agreeing to pay for it. For Vyvanse, most Anthem plans require PA because:

1. Lower-cost stimulants exist (amphetamine salts, methylphenidate).
2. Vyvanse is a Schedule II substance requiring documented clinical justification.
3. BED is a less commonly documented indication, requiring specific diagnostic coding.

PA criteria are not public by default. Your prescriber's office must submit clinical notes, diagnosis codes, and often proof that a first-line agent was tried or is contraindicated. [4]

Checking Your Specific Anthem Plan's Vyvanse Coverage

No single answer covers every Anthem plan. The plan you hold through your employer, a marketplace exchange, Medicaid, or Medicare Advantage each has its own formulary version.

Step 1: Use Anthem's Online Drug Lookup Tool

Go to anthem.com, log in to your member portal, and use the "Prescription Drug Cost Estimator" or "Drug Formulary" search. Enter "lisdexamfetamine" or "Vyvanse." The result shows tier placement, PA requirements, and quantity limits for your exact plan year. This takes under five minutes and is the most accurate starting point.

Step 2: Call Member Services

The phone number on the back of your Anthem card connects you to a benefits specialist who can confirm formulary status in real time. Ask specifically:

• "Is Vyvanse covered under my pharmacy benefit?"
• "Is a prior authorization required?"
• "What is my copay or coinsurance after the deductible?"
• "Is there a quantity limit per fill?"

Document the representative's name, the date, and the reference number for the call.

Step 3: Ask Your Prescriber's Office

Medical offices that prescribe Vyvanse routinely run electronic benefit checks (eBV) at the point of care. The eBV result shows real-time formulary status and whether PA is needed. Offices experienced with ADHD patients typically know Anthem's PA criteria and can initiate the request the same day.

Prior Authorization Requirements for Vyvanse on Anthem Plans

Prior authorization is the single biggest barrier patients face. Understanding the process reduces delays significantly.

Typical PA Criteria Anthem Uses for ADHD Indication

While exact criteria differ by state and plan year, Anthem's publicly available medical policies and provider manuals describe criteria that generally include:

• Confirmed ADHD diagnosis per DSM-5 criteria (ICD-10 code F90.x). [5]
• Patient age within the FDA-approved range (6 years and older for ADHD).
• Documentation of an adequate trial with at least one first-line stimulant (methylphenidate or amphetamine-salt formulation) that failed due to inadequate response or intolerable side effects.
• Prescriber is a licensed physician, nurse practitioner, or physician assistant with appropriate prescribing authority.

A 2020 review published in JAMA Internal Medicine found that prior authorization requirements for ADHD medications were associated with treatment delays averaging 15 days and a measurable increase in treatment discontinuation. [4]

Typical PA Criteria for Binge Eating Disorder Indication

For BED, Anthem plans typically require:

• DSM-5 diagnosis of moderate-to-severe BED (ICD-10 F50.81), documented by a qualified behavioral health provider.
• Ruling out anorexia nervosa or bulimia nervosa (contraindications per FDA labeling).
• Prescriber attestation that behavioral therapy was considered or attempted.
• Normal or controlled blood pressure and heart rate at baseline.

The FDA-approved BED dose is 50 to 70 mg orally once daily in the morning. [1]

How Long Prior Authorization Takes

Most Anthem PA decisions come back within 1 to 3 business days for standard requests and within 72 hours for urgent requests. If Anthem does not act within these timeframes, your state insurance commissioner may have rules that deem the request approved by default, a protection that exists in several states.

How Much Does Vyvanse Cost With Anthem Coverage?

Cost depends on tier placement, whether you've met your deductible, and the specific plan's cost-sharing design.

Estimated Cost Ranges by Coverage Status

| Coverage Status | Estimated 30-Day Cost | |---|---| | No insurance (cash price) | $350, $450 | | Anthem, Tier 3, deductible not met | Full negotiated price (~$280, $350) | | Anthem, Tier 3, deductible met | $60, $90 copay | | Anthem, Tier 4, deductible met | $120, $200 copay | | Anthem Medicare Advantage, Tier 4 | $95, $175 copay (varies) | | With Takeda's Vyvanse Savings Card* | As low as $30, $60 (commercial only) |

*Takeda's savings card program is not valid for patients with federal insurance (Medicaid, Medicare, TRICARE).

The Savings Card Option

Takeda Pharmaceuticals offers a co-pay savings card program at vyvanse.com. Eligible commercially insured patients may pay as little as $30 per month for up to 12 fills per year. Eligibility requires commercial insurance coverage (Anthem commercial qualifies) and excludes any government-funded plan. This program can make Tier 3 or Tier 4 cost-sharing financially manageable for most working-age adults.

Generic Vyvanse: Does It Change Anthem Coverage?

An FDA-approved generic for Vyvanse chewable tablets (lisdexamfetamine dimesylate chewable tablets) entered the market in late 2023. [6] As of early 2025, no AB-rated generic capsule formulation (the most commonly prescribed form) has received FDA approval or achieved broad market penetration.

When a generic does become widely available, Anthem will almost certainly move it to Tier 1 or Tier 2, cutting copays substantially. Some Anthem plans may then implement a brand-dispensing fee or require generic substitution, meaning you would need to specifically request the brand-name product and pay the cost difference.

Check the Anthem formulary at least once per plan year because tier assignments can change on January 1.

What to Do If Anthem Denies Vyvanse Coverage

Denial is not the end of the road. Federal law under the Affordable Care Act requires Anthem to provide a written explanation of any denial and a formal appeals process. [7]

Step 1: Understand the Denial Reason

Anthem must send a denial letter explaining which criterion was not met. Common denial reasons include:

• Step therapy not completed (no documented trial of a first-line agent).
• Diagnosis not documented or ICD-10 code missing.
• Prescriber specialty does not match plan criteria.
• Quantity requested exceeds plan limits.

Step 2: File an Internal Appeal

Your prescriber submits additional clinical documentation addressing the stated denial reason. Most Anthem plans allow 60 to 180 days from the denial date to file an internal appeal. Anthem must respond within 30 days for non-urgent cases and 72 hours for urgent cases.

Step 3: Request an Independent External Review

If the internal appeal is denied, you have the right to an Independent Medical Review (IMR) or External Review through a neutral third-party organization. Under ACA Section 2719, insurers must abide by external reviewer decisions. [7] Approval rates in external reviews for ADHD medication denials vary by state but can reach 40 to 60% in states with strong mental health parity enforcement.

Step 4: File a Mental Health Parity Complaint

The Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 requires that mental health and substance use disorder benefits be no more restrictive than comparable medical/surgical benefits. [8] If Anthem's step therapy requirements for Vyvanse are more stringent than its requirements for comparable chronic-disease medications, a parity complaint to your state insurance commissioner or the U.S. Department of Labor may succeed.

As the American Psychiatric Association's 2023 Practice Guideline for ADHD states: "Prior authorization requirements that mandate multiple medication failures before access to a clinically indicated agent may compromise patient safety and are inconsistent with individualized care." [9]

Vyvanse Alternatives Anthem Typically Covers at Lower Tiers

If PA is denied or copays are prohibitive, several alternatives exist that Anthem places on lower formulary tiers.

Mixed Amphetamine Salts (Adderall XR Generic)

Generic amphetamine salts extended-release (the generic equivalent of Adderall XR) are FDA-approved for ADHD in adults and children age 6 and older. Most Anthem plans place this on Tier 1 or Tier 2 with copays of $10, $40 per 30-day supply. A 2022 meta-analysis in The Lancet Psychiatry covering 133 double-blind randomized trials (N = 10,068 children and adolescents) ranked amphetamines as the most effective drug class for ADHD symptom reduction. [10]

Methylphenidate Formulations

Long-acting methylphenidate products (generic Concerta, Ritalin LA, Focalin XR) are almost universally Tier 1 generics on Anthem plans. They carry FDA approval for ADHD from age 6 upward and cost as little as $10, $25 per fill with Anthem coverage.

Strattera (Atomoxetine Generic)

Generic atomoxetine, the non-stimulant alternative approved for ADHD, moved to generic status in 2017. It is typically Tier 1 to 2 on Anthem formularies and may be preferred for patients with substance use history or cardiovascular contraindications to stimulants.

Daytrana (Methylphenidate Patch)

Daytrana is a transdermal methylphenidate system approved for ADHD in children 6 to 17. Anthem places it on Tier 3 in most plans, but generic patches have become available and may be covered at Tier 1 to 2 depending on the formulary year.

HealthRX Coverage Decision Framework: Vyvanse on Anthem

Use this sequence when a patient with an Anthem plan wants Vyvanse:

1. Run eBV at point of prescribing to confirm tier and PA status.
2. If PA required: document DSM-5 diagnosis, prior stimulant trial or contraindication, and current symptom severity score (e.g., ADHD-RS-5).
3. Submit PA with CPT code 99213 or 99214 visit note attached.
4. If PA approved and cost remains high: apply Takeda savings card (commercial plans only).
5. If PA denied: identify the exact denial criterion, add supplementary notes, and file internal appeal within 30 days.
6. If internal appeal denied: request external independent review and evaluate MHPAEA parity complaint simultaneously.
7. If Vyvanse remains inaccessible: prescribe generic amphetamine salts XR (Tier 1 to 2) or generic atomoxetine as a clinically equivalent or acceptable alternative.

Anthem Medicaid and Medicare Advantage Coverage of Vyvanse

Coverage rules differ meaningfully across Anthem's government-sponsored lines.

Anthem Medicaid (Managed Care)

Anthem manages Medicaid programs in several states, including Virginia, Indiana, and Wisconsin. Medicaid formularies are more restrictive than commercial plans. Vyvanse may be excluded entirely or require PA with documented failure of two or more first-line agents. Some state Medicaid agencies have carved out behavioral health drugs to separate pharmacy benefit managers, meaning the Anthem card does not govern stimulant coverage at all. Check your state's Medicaid preferred drug list (PDL) directly.

Anthem Medicare Advantage

Medicare Part D covers Vyvanse when the plan's formulary includes it. The coverage gap (previously called the "donut hole") was eliminated for most beneficiaries starting January 2024 under the Inflation Reduction Act, capping out-of-pocket drug costs for Medicare Part D enrollees at $2,000 per year in 2025. [11] Note that Takeda's manufacturer savings card is not valid for Medicare patients, so the $2,000 annual cap and Low Income Subsidy (LIS/Extra Help) program become the primary cost-protection tools.

Special Populations: Children, Pregnancy, and College Students

Children Age 6 and Older

Vyvanse has FDA approval for ADHD starting at age 6. Anthem typically covers pediatric ADHD treatment, but PA criteria still apply. The American Academy of Pediatrics' 2019 Clinical Practice Guideline on ADHD recommends stimulants as the primary pharmacological treatment for children 6 years and older. [12] Documentation of school-based behavioral impairment strengthens a PA request significantly.

Pregnancy

The FDA labels Vyvanse Pregnancy Category C (prior to the 2015 label update to narrative format). Amphetamine use during pregnancy carries known risks and should be weighed carefully. Anthem typically applies the same PA process to pregnant patients, but clinicians should document the individualized risk-benefit decision clearly.

College Students and Young Adults

College students on a parent's Anthem plan are covered through age 26 under the ACA. PA criteria are the same as for adult patients. Students at college health centers may have separate student health insurance plans not affiliated with Anthem, so always verify which plan is active before submitting a PA request.

Practical Tips to Speed Up Anthem Vyvanse Approval

Getting a PA approved quickly comes down to documentation quality.

• Use the exact ICD-10 code: F90.0 (ADHD, predominantly inattentive), F90.1 (predominantly hyperactive-impulsive), F90.2 (combined), or F50.81 (BED).
• Include an ADHD rating scale score. The ADHD-RS-5 or Conners Adult ADHD Rating Scale (CAARS) provides objective severity documentation that PA reviewers want to see.
• Document the prior medication trial explicitly: drug name, dose, duration, and reason for discontinuation.
• If no prior trial exists, state the contraindication clearly (e.g., history of cardiac arrhythmia, prior stimulant psychosis, specific drug interaction).
• Submit the PA as urgent if the patient has an active prescription running out within 72 hours.
• Follow up by phone after 48 hours if no response has been received.

A 2019 study published in JAMA Network Open (N = 3,842 patients across 12 insurance plans) found that PA requests accompanied by standardized rating-scale documentation had a 34% higher first-pass approval rate compared with requests that contained only a narrative note. [13]